口腔颌面外科杂志2012，Vol.22Issue(2)：77-81,5.DOI:10.3969/j.issn.1005-4979.2012.02.001
晚期口腔颌面-头颈部鳞癌靶向治疗的进展浅析
Advances of Targeted Therapies in Squamous Cell Carcinoma of Oral and Maxillofacial-Head and Neck
摘要
Abstract
The treatment of advanced oral and maxillofacial-head and neck squamous cell carcinoma (SCCHN) is still a challenge in the section of oncology in oral and maxillofacial surgery. Although the traditional treatments like radical surgical operation combined with radiotherapy or chemotherapy has progressed a lot recently, the prognosis of the advanced SCCHN is still poor. However, the progress of target drugs brings hope for it. Two primary strategies have emerged that account for most of the success of current targeted therapies: one is epidermal growth factor receptor (EGFR), and the other is vascular endothelial growth factor (VEGF) receptor. The typical drugs to block EGFR are cetuximab and nimotuzumab, both of them have demonstrated survival benefits across whatever monotherapy, or multitherapy with radiotherapy or chemotherapy. The typical drug to block VEGF is bevacizumab, which is now proceeding through Phase Ⅲ clinical trial. The targeted therapy is a new choice for the advanced SCCHN.关键词
口腔颌面-头颈部鳞癌/靶向治疗/表皮生长因子受体/血管内皮生长因子受体/西妥昔单抗/尼妥珠单抗/贝伐单抗Key words
squamous cell carcinoma of oral and maxillofacial-head and neck/ targeted therapy/ epidermal growth factor receptor(EGFR)/ vascular endothelial growth factor receptor (VEGF)/ cetuximab/ nimotuzumab/ bevacizumab分类
医药卫生引用本文复制引用
郭伟..晚期口腔颌面-头颈部鳞癌靶向治疗的进展浅析[J].口腔颌面外科杂志,2012,22(2):77-81,5.基金项目
上海市科学技术委员会科研资助项目(10410711200,11495802000) （10410711200,11495802000）
